Program
sacituzumab govitecan
Also written as “Sacituzumab Govitecan-hziy”, “Sacituzumab Govitecan” and “Sacituzumab Govitecan-hziy (SG)”.
Its studies are mostly in Triple Negative Breast Neoplasms · Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Carcinoma, Transitional Cell · Neoplasm Metastasis, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciences | 2317 open or running | phase 4since Mar 19, 2020 | Jun 26, 2012 | Dec 2026phase 1 · NCT04617522 |
| Merck | 11 open or running | phase 3since Nov 2, 2022 | Nov 2, 2022 | Jan 12, 2027phase 3 · NCT05609968 |
Also a collaborator on its studies: Pfizer, Merck KGaA, Darmstadt, Germany and Arcus Biosciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 9 studies since Jun 26, 2012.
- Nov 2, 2020Phase 1 study in Neoplasm MetastasisGilead Sciences · NCT04617522 · 30 planned · United States, France, Italy and more
- Nov 17, 2020Phase 3 study in Breast NeoplasmsGilead Sciences · NCT04639986 · 331 enrolled · China, South Korea, Taiwan
- Oct 11, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungGilead Sciences · NCT05089734 · 603 enrolled · United States, Australia, Austria and more
- Oct 19, 2021Phase 2 study in Triple Negative Breast NeoplasmsGilead Sciences · NCT05101096 · 135 enrolled · Japan
- Nov 3, 2021Phase 2 study in Solid TumorGilead Sciences · NCT05119907 · 53 enrolled · China
- Dec 23, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungGilead Sciences · NCT05186974 · 193 enrolled · United States, Australia, Canada and more
- May 16, 20222 phase 3 studies in Triple Negative Breast NeoplasmsGilead Sciences · NCT05382299, NCT05382286
- Nov 2, 2022Merck’s first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to MerckMerck · NCT05609968 · 614 enrolled · United States, Australia, Brazil and more
- Nov 21, 2022Phase 2 study in Lung NeoplasmsGilead Sciences · NCT05633667 · 192 enrolled · United States, Brazil, Hong Kong and more
- Nov 21, 2022Phase 3 study in Triple Negative Breast NeoplasmsGilead Sciences · NCT05633654 · 1,514 planned · United States, Australia, Belgium and more
- Apr 21, 2023Phase 3 study in Breast NeoplasmsGilead Sciences · NCT05840211 · 654 enrolled · United States, Argentina, Australia and more
- Jun 27, 2024Phase 3 study in Endometrial NeoplasmsGilead Sciences · NCT06486441 · 640 enrolled · United States, Australia, Brazil and more
- Jan 24, 2025Phase 3 study in Extensive Stage Small Cell Lung Cancer (ES-SCLC)Gilead Sciences · NCT06801834 · 695 planned · United States, Argentina, Australia and more
- Apr 8, 2025Phase 2 study in Triple Negative Breast NeoplasmsGilead Sciences · NCT06926920 · 100 planned · United States, Australia, South Korea
Ahead
- Dec 2026Primary completion: phase 3 study in Breast NeoplasmsGilead Sciences · NCT04639986
- Dec 2026Primary completion: phase 1 study in Neoplasm MetastasisGilead Sciences · NCT04617522
- Jan 12, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungMerck · NCT05609968
- Feb 2027Primary completion: phase 3 study in Triple Negative Breast NeoplasmsGilead Sciences · NCT05382286
TargetBeta
“Tumor-associated calcium signal transducer 2 binding agent”ChEMBL 37, by rule
Other programs on TACSTD2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sacituzumab tirumotecan | Merck | phase 3 | 50 |
| datopotamab deruxtecanrule | AstraZeneca | phase 3 | 28 |
| JSKN016rule | Alphamab Oncology | phase 3 | 5 |
| Anti-TROP2 Antibody-drug Conjugate ESG401rule | Qilu Pharmaceutical | phase 3 | 3 |
| Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036Crule | Minghui Pharmaceutical | phase 2 | 3 |
| sacituzumab drozuntecanrule | dualitybio-inc | phase 2 | 2 |
| Anti-TROP-2 Antibody-drug Conjugate OBI-902rule | obi-pharma-inc | phase 2 | 1 |
| Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103rule | avenzo-therapeutics-inc | phase 2 | 1 |
| Anti-TROP2/Topoisomerase I Inhibitor-STING Agonist Immunostimulatory ADC ASP2998rule | Astellas Pharma | phase 2 | 1 |
| JSKN016HCrule | Alphamab Oncology | phase 1 | 1 |
| KH815rule | Chengdu Kanghong Pharmaceutical Group | phase 1 | 1 |
Studies
All 24 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06926920Triple Negative Breast Neoplasms · United States, Australia, South Korea | 2 | Recruiting | Gilead Sciences | Jun 2028 | 100 |
| NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC) · United States, Argentina, Australia and more | 3 | Recruiting | Gilead Sciences | Oct 2029 | 695 |
| NCT06486441Endometrial Neoplasms · United States, Australia, Brazil and more | 3 | Active, not recruiting | Gilead Sciences | Jun 2029 | 640 |
| NCT05840211Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Gilead Sciences | Apr 2028 | 654 |
| NCT05633667Lung Neoplasms · United States, Brazil, Hong Kong and more | 2 | Active, not recruiting | Gilead Sciences | Sep 2029 | 192 |
| NCT05633654Triple Negative Breast Neoplasms · United States, Australia, Belgium and more | 3 | Recruiting | Gilead Sciences | Jun 2027 | 1,514 |
| NCT05609968Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more | 3 | Active, not recruiting | Merck | Jan 12, 2027 | 614 |
| NCT05382299Triple Negative Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Gilead Sciences | Jul 2028 | 623 |
| NCT05382286Triple Negative Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Gilead Sciences | Feb 2027 | 443 |
| NCT05186974Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more | 2 | Active, not recruiting | Gilead Sciences | Mar 2027 | 193 |
| NCT05119907Solid Tumor · China | 2 | Active, not recruiting | Gilead Sciences | Oct 2026 | 53 |
| NCT05101096Triple Negative Breast Neoplasms · Japan | 2 | Active, not recruiting | Gilead Sciences | May 2027 | 135 |
| NCT05089734Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more | 3 | Active, not recruiting | Gilead Sciences | Nov 29, 2023 | 603 |
| NCT04639986Breast Neoplasms · China, South Korea, Taiwan | 3 | Active, not recruiting | Gilead Sciences | Dec 2026 | 331 |
| NCT04617522Neoplasm Metastasis · United States, France, Italy and more | 1 | Recruiting | Gilead Sciences | Dec 2026 | 30 |
| NCT04527991Locally Advanced or Metastatic Unresectable Urothelial Cancer · United States, Australia, Austria and more | 3 | Completed | Gilead Sciences | Jul 4, 2025 | 711 |
| NCT04454437Triple Negative Breast Neoplasms · China | 2 | Active, not recruiting | Gilead Sciences | Aug 6, 2021 | 80 |
| NCT04319198Metastatic Solid Tumors · United States, Belgium, France | 4 | Completed | Gilead Sciences | Oct 18, 2024 | 25 |
| NCT03964727Neoplasm Metastasis · United States, Australia, Belgium and more | 2 | Active, not recruiting | Gilead Sciences | Jan 15, 2025 | 227 |
| NCT03901339Breast Neoplasms · United States, Belgium, Canada and more | 3 | Completed | Gilead Sciences | Oct 20, 2023 | 543 |
| NCT03547973Metastatic Urothelial Cancer · United States, France, Germany and more | 2 | Active, not recruiting | Gilead Sciences | Apr 2030 | 502 |
| NCT02574455Breast Neoplasms · United States, Belgium, Canada and more | 3 | Completed | Gilead Sciences | Mar 30, 2020 | 529 |
| NCT02161679Triple Negative Breast Neoplasms | 2 | Withdrawn | Gilead Sciences | Aug 2016 | 0 |
| NCT01631552Esophageal Neoplasms · United States | 2 | Completed | Gilead Sciences | Mar 1, 2019 | 515 |
How it is read
Names in the registry
- “Sacituzumab Govitecan-hziy”, 12 entries
- “Sacituzumab Govitecan”, 4 entries
- “Sacituzumab Govitecan-hziy (SG)”, 4 entries
- “Sacituzumab govitecan-hziy (SG)”, 2 entries
- “Sacituzumab Govitecan (SG)”, 2 entries
Conditions, from the studies’ own filings
- Triple Negative Breast Neoplasms, 7 studies
- Breast Neoplasms, 5 studies
- Carcinoma, Non-Small-Cell Lung, 5 studies
- Carcinoma, Transitional Cell, 2 studies
- Neoplasm Metastasis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.